BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 10654007)

  • 1. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.
    Takahashi M; Yoshizawa H; Tanaka H; Tanaka J; Kagamu H; Ito K; Shimbo T; Chou D; Wakabayashi M; Suzuki E; Sakai K; Arakawa M; Gejyo F
    Bone Marrow Transplant; 2000 Jan; 25(1):5-11. PubMed ID: 10654007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer.
    Bessho A; Ueoka H; Kiura K; Tabata M; Sunami K; Katayama Y; Yamane H; Hiraki A; Harada M
    Anticancer Res; 1999; 19(1B):693-8. PubMed ID: 10216478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
    Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; Gonin R; McCauley M; Mazanet R; Schnipper L; Frei E
    Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
    Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; McCauley M; Mazanet R; Schnipper L; Frei E; Antman KH
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):83-5. PubMed ID: 7992072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
    Strauss GM; Lynch TJ; Elias AD; Jacobs C; Kwiatkowski DJ; Shulman LN; Carey RW; Grossbard ML; Jauss S; Sugarbaker DJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):70-4. PubMed ID: 7544029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
    Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
    Elias AD; Wheeler C; Ayash LJ; Schwartz G; Ibrahim J; Mills L; McCauley M; Coleman N; Warren D; Schnipper L; Antman KH; Teicher BA; Frei E
    Clin Cancer Res; 1998 Jun; 4(6):1443-9. PubMed ID: 9626461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
    Fields KK; Elfenbein GJ; Perkins JB; Janssen WE; Ballester OF; Hiemenz JW; Zorsky PE; Kronish LE; Foody MC
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):86-92. PubMed ID: 7527592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
    Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
    Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer.
    Lorigan P; Woll PJ; O'Brien ME; Ashcroft LF; Sampson MR; Thatcher N
    J Natl Cancer Inst; 2005 May; 97(9):666-74. PubMed ID: 15870437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
    Demirer T; Ilhan O; Mandel NM; Arat M; Günel N; Celebi H; Ustün C; Akan H; Demirer S; Aydintuğ S; Uysal A; Koç H
    Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas.
    Bokemeyer C; Franzke A; Hartmann JT; Schöber C; Arseniev L; Metzner B; Link H; Kanz L; Schmoll HJ
    Cancer; 1997 Oct; 80(7):1221-7. PubMed ID: 9317171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
    Miller AA; Al Omari A; Murry DJ; Case D
    Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
    Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
    J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
    Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
    Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mega-dose chemotherapy with peripheral blood stem cell transplantation (PBS-CT) for small cell lung cancer (SCLC)].
    Chou T; Yokoyama A; Yoshizawa H; Hoshino M; Ebe T; Kurita Y; Arakawa M
    Gan To Kagaku Ryoho; 1995 Oct; 22(12):1741-8. PubMed ID: 7574804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma. A study of the Lung Cancer Study Group of West Japan.
    Katakami N; Takada M; Negoro S; Ota K; Fujita J; Furuse K; Ariyoshi Y; Ikegami H; Fukuoka M
    Cancer; 1996 Jan; 77(1):63-70. PubMed ID: 8630941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.